A Phase 1, Open-Label Study in Hemodialysis and Non-Hemodialysis Patients With Severe Chronic Kidney Disease to Evaluate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs KBP 5074 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors KBP Biosciences
- 08 Mar 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.